A PET Study With ORM-12741

Phase 1 Completed 26 enrolled Orion Corporation, Orion Pharma

Non-randomizedParallel-groupOpen-label

Summary

The purpose of the study is to evaluate the effect of ORM-12741 on receptor occupancy by positron emission tomography with different doses and plasma concentrations. The pharmacokinetic profile and safety will also be evaluated.

Timeline

Start: 2009-01
Primary completion: 2009-06
Completion: 2009-06

Publications

Shahid M, Rinne JO, Scheinin M, Virta J, Marjamaki P, Solin O, Arponen E, Sallinen J, Kuokkanen K, Rouru J. Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the alpha2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ORM-12741	Small molecule	—	Oral

Indications

No indication recorded.